Biognosys at ENA 2020 - Biognosys

Biognosys at ENA 2020

BIOGNOSYS POSTERS

High-Resolution Limited Proteolysis (HR-LIP): A Novel Approach for Target Validation and Lead Compound Optimization

Y. Feng1, N. Beaton1, J. Adhikari2, R. Bruderer1, R. Tomlinson2, I. Cornella-Taracido2, L. Reiter1.

1) Biognosys AG, Schlieren, Switzerland.
2) Cedilla Therapeutics, Cambridge, USA.

 

LiP-Quant, an Automated Chemoproteomic Approach to Identify Drug Targets in Complex Proteomes

Y. Feng1, N. Beaton1, I. Piazza2, R. Bruderer1, P. Picotti2, L. Reiter1.

1) Biognosys, Schlieren, Switzerland.
2) ETH Zurich, Institute of Molecular Systems Biology, Zurich, Switzerland.

 

 

MORE INFORMATION

 

More information about our Limited Proteolysis (LiP) technology is available

 

Here

Helpdesk

Access our knowledge base with relevant resources and guiding information.

Contact

    Close banner

    New: Drug Target Validation

    Reveal Binding Sites with Structural Proteomics

    New: Drug Target Validation

    Reveal Compound Binding Sites with Structural Proteomics

    Learn More